Aung FootHealth initiates enrollment in diabetic foot ulcers trial

The Matrix (A Phase IIb Study of GAM501 in the treatment of diabetic ulcers in the lower extremities) trial is a randomized, double-blind, placebo-controlled, comparator arm (standard of care) safety and efficacy study to evaluate GAM501 that is topically administered once or twice over the course of the study. The Matrix trial will study the effects of Excellarate (GAM501) for the potential treatment of patients with neuropathic non-healing diabetic foot ulcers. The primary endpoint will be the effect of Excellarate on the incidence of complete ulcer closure at 12 weeks or earlier.

Aung FootHealth Clinics & Advanced Wound Care Center is among an estimated 25 sites participating in the Matrix trial. The trial is expected to enroll 210 patients nationwide. Excellarate is an investigational product designed to stimulate the process of wound healing.